ABBV-701 for Healthy Subjects
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. However, since the trial is for healthy participants, it's possible that taking medications could affect eligibility.
What safety data exists for ABBV-701 or similar treatments?
Adeno-associated virus (AAV) gene therapies, which include treatments like ABBV-701, have shown promise but also raised safety concerns. Some studies report no major safety issues, while others note serious adverse events, including deaths, highlighting the need for consistent safety monitoring.12345
What is the purpose of this trial?
The main objective of this study is to assess the safety, tolerability, pharmacokinetics, and immunogenicity of subcutaneous (SC) ABBV-701 in healthy adult western and Asian participants.
Research Team
ABBVIE INC.
Principal Investigator
AbbVie
Eligibility Criteria
This trial is for healthy adults from Western and Asian backgrounds. Specific eligibility criteria are not detailed, but typically participants must meet certain health standards and not have conditions that could interfere with the study.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single ascending subcutaneous dose of ABBV-701 or placebo
Follow-up
Participants are monitored for safety, tolerability, pharmacokinetics, and immunogenicity after treatment
Treatment Details
Interventions
- ABBV-701
Find a Clinic Near You
Who Is Running the Clinical Trial?
AbbVie
Lead Sponsor
Dr. Roopal Thakkar
AbbVie
Chief Medical Officer since 2023
MD from Wayne State University School of Medicine
Robert A. Michael
AbbVie
Chief Executive Officer
Bachelor's degree in Finance from the University of Illinois